Cartesian Therapeutics (RNAC) highlighted its recent progress and outlined its 2025 strategic priorities across its pipeline of mRNA cell therapy product candidates. Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deepening responses observed over time in Descartes-08-treated participants in Phase 2b trial in myasthenia gravis; Safety profile continues to support outpatient administration based on updated data shared in December 2024 ; Phase 2 systemic lupus erythematosus trial of Descartes-08 ongoing with expected data readout in 2H25; Cash resources expected to support planned operations, including completion of planned Phase 3 trial for Descartes-08 for myasthenia gravis, into mid-2027
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics announces employment inducement grants
- Cartesian Therapeutics initiated with a Buy at BTIG
- Cartesian Therapeutics files to sell 11.39M shares of common stock for holders
- Cartesian Therapeutics files to sell 6.25M shares of common stock for holders
- Cartesian Therapeutics files $400M mixed securities shelf